In Israel and Pennyslvania, Rosetta Genomics has entered into a share transfer agreement with unnamed purchasers, under which it has sold all of the ordinary shares of Rosetta Green it held. Rosetta Genomics had owned approximately 50.03% of the outstanding ordinary shares of Rosetta Green, which is publicly traded on the Tel Aviv Stock Exchange.
Rosetta Genomics received an upfront payment of $900,000 for their shares. In addition, Rosetta Genomics could be entitled to a payment of $2,000,000 if Rosetta Green is acquired within three years and if certain other conditions are met in connection with such acquisition.
More background on the story from the Digest
Category: Chems & Materials